347 related articles for article (PubMed ID: 16490849)
21. Delayed eczematous skin reaction as an adverse drug reaction to immunoglobulin infusions: A case series.
Barthel C; Musquer M; Veyrac G; Bernier C
Ann Dermatol Venereol; 2022 Dec; 149(4):264-270. PubMed ID: 35753818
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
Sapir T; Blank M; Shoenfeld Y
Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
[TBL] [Abstract][Full Text] [Related]
23. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria.
Pereira C; Tavares B; Carrapatoso I; Loureiro G; Faria E; Machado D; Chieira C
Eur Ann Allergy Clin Immunol; 2007 Sep; 39(7):237-42. PubMed ID: 18237000
[TBL] [Abstract][Full Text] [Related]
24. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case.
Brazzelli V; Grassi S; Savasta S; Ruffinazzi G; Carugno A; Barbaccia V; Marseglia GL; Borroni G
Int J Immunopathol Pharmacol; 2014; 27(1):127-30. PubMed ID: 24674688
[TBL] [Abstract][Full Text] [Related]
25. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
26. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases.
Sherer Y; Kuechler S; Jose Scali J; Rovensky J; Levy Y; Zandman-Goddard G; Shoenfeld Y
Isr Med Assoc J; 2008 Jan; 10(1):55-7. PubMed ID: 18300575
[TBL] [Abstract][Full Text] [Related]
27. Intravenous immunoglobulin-induced severe vesicular eczematous eruption successfully treated with narrow band-ultraviolet B therapy.
Koizumi R; Fukumoto T; Jimbo H; Nishigori C
Photodermatol Photoimmunol Photomed; 2021 Sep; 37(5):371-373. PubMed ID: 33559335
[TBL] [Abstract][Full Text] [Related]
28. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients.
Duronio A; Bajjoka I; Hsaiky L; Parasuraman R
Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157
[TBL] [Abstract][Full Text] [Related]
29. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
Bystryn JC; Jiao D
Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of intravenous immunoglobulin treatment in refractory uveitis.
Onal S; Foster CS; Ahmed AR
Ocul Immunol Inflamm; 2006 Dec; 14(6):367-74. PubMed ID: 17162608
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
32. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Barsheshet A; Marai I; Appel S; Zimlichman E
Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
[TBL] [Abstract][Full Text] [Related]
33. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.
Toubi E; Kessel A; Shoenfeld Y
Hum Immunol; 2005 Apr; 66(4):395-402. PubMed ID: 15866703
[TBL] [Abstract][Full Text] [Related]
34. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation.
Chapman SA; Gilkerson KL; Davin TD; Pritzker MR
Ann Pharmacother; 2004 Dec; 38(12):2059-67. PubMed ID: 15536143
[TBL] [Abstract][Full Text] [Related]
35. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits.
Yip LW; Thong BY; Tan AW; Khin LW; Chng HH; Heng WJ
Eye (Lond); 2005 Aug; 19(8):846-53. PubMed ID: 15389280
[TBL] [Abstract][Full Text] [Related]
36. Vesicular eczema after intravenous immunoglobulin therapy for treatment of Stevens-Johnson syndrome.
Young PK; Ruggeri SY; Galbraith S; Drolet BA
Arch Dermatol; 2006 Feb; 142(2):247-8. PubMed ID: 16490861
[No Abstract] [Full Text] [Related]
37. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura.
Bierling P; Godeau B
Hum Immunol; 2005 Apr; 66(4):387-94. PubMed ID: 15866702
[TBL] [Abstract][Full Text] [Related]
38. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
Daphnis E; Stylianou K; Alexandrakis M; Xylouri I; Vardaki E; Stratigis S; Kyriazis J
Nephron Clin Pract; 2007; 106(4):c143-8. PubMed ID: 17596722
[TBL] [Abstract][Full Text] [Related]
39. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
40. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
